What question did this study set out to answer?

February 17, 2026Journal of Clinical Investigation0 citationsOpen Access

Predicting checkpoint inhibitor-associated autoimmune diabetes: prospects and limitations

Key Points

This research aims to identify predictors of checkpoint inhibitor-associated autoimmune diabetes in patients receiving cancer treatment.
Examined serum and PBMCs from 14 ICI-treated patients with autoimmune diabetes and 28 matched controls.
Identified variables present prior to ICI treatment that are linked to autoimmune diabetes development.
Reduced pancreatic volume was identified as a predictor.
Presence of islet autoantibodies was noted in patients who developed the condition.
Biomarkers indicating immune cell activation predicted the risk of autoimmune diabetes.

Abstract

Checkpoint inhibitor–associated autoimmune diabetes (CIADM) is a life-altering and potentially life-threatening complication of immune checkpoint inhibitor (ICI) treatment in patients with cancer. Risk factors and predictors of this complication remain largely unknown. In this issue of the JCI , Wu et al. examined serum and PBMCs from 14 ICI-treated patients who developed CIADM and 28 matched controls. They identified several variables that were present prior to ICI treatment, including reduced pancreatic volume, islet autoantibodies, and biomarkers indicating immune cell activation, that together are highly predictive of development of CIADM. These findings could have profound clinical implications including treatment decisions, monitoring, and potential future prevention strategies.

Ask AI

Helpful

Bookmark

View Full Paper